Status:

RECRUITING

The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care

Lead Sponsor:

Brigham and Women's Hospital

Conditions:

Human Immunodeficiency Virus

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this clinical trial is to learn if the DSD model (SUSTAIN-DSD) is effective in improving participants HIV treatment adherence. The main questions it aims to answer are: * Does the SUSTAIN...

Detailed Description

Differentiated Service Delivery (DSD) models have been shown to provide equivalent or better retention in healthcare and viral (VL) suppression for people with HIV than conventional care models. Howev...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Adults (≥18 years or age)
  • Living with HIV
  • On a dolutegravir-based first-line ART regimen
  • Evidence of a care gap (\>28 days late for appointment) or having a raised viral load (≥50 copies/ml) in the preceding year, either from SUSTAIN study data or from clinic records.
  • Able to provide full informed consent.
  • Willingness to comply with study procedures, including providing regular update of contact details or locator information.
  • A purposively selected subset of 30 enrolled participants will be invited for a semi-structured, in-depth interview at (or within 2 months after) the month 24 visit (for experience and perceptions; aim 2); and 20 different participants will be invited to participate in in-depth interviews to determine acceptability and feasibility (aim 3) within the same time frame.
  • Exclusion Criteria at Enrollment:
  • Clinical conditions as assessed by the ART clinicians as requiring clinic-based follow-up e.g. tuberculosis or epilepsy.
  • Pregnant at enrollment and requiring care in the antenatal clinic system.
  • Sustained retention in care (no gaps of \>28days) and viral suppression in the preceding year.
  • Plans to leave Cape Town permanently within the next 24 months.

Exclusion

    Key Trial Info

    Start Date :

    November 14 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 31 2029

    Estimated Enrollment :

    310 Patients enrolled

    Trial Details

    Trial ID

    NCT06554223

    Start Date

    November 14 2025

    End Date

    March 31 2029

    Last Update

    November 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Cape Town

    Cape Town, South Africa